Selecting Therapy for Less Common Driver Mutations in Advanced Lung Cancer: MET, RET, ALK, ROS, NTRK

Source: Biomarker-Driven Lung Cancer Care: Application of New Standards and the Latest Research
Download Slideset
Download these slides from a live webinar for the most recent data on optimal treatment approaches for patients with NSCLC that are positive for less common driver mutations, including MET, RET, ALK, ROS, and NTRK.
Todd M. Bauer, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 2.17 MB
Released: June 5, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
Lilly
Novartis Pharmaceuticals Corporation
Turning Point Therapeutics, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings